Personalized Lymphoma Vaccine (Id-KLH/GM-CSF)
Targeting the Treatment of Certain B-Cell Lymphomas including
Follicular Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
What is BiovaxID?
As a result of its collaboration with the U.S. National Cancer Institute (NCI), Biovest is developing BiovaxID® as a late-stage (Phase III), personalized therapeutic cancer vaccine for the treatment of non-Hodgkin’s lymphoma, specifically targeting follicular lymphoma, mantle cell lymphoma and potentially other B-cell blood cancers.
BiovaxID represents the first of a new class of cancer vaccines designed to extend disease-free survival by seeking to establish immune dominance over malignant lymphoma B-cells following treatment with standard regimens such as chemotherapy and anti-CD20 monoclonal antibodies.
The goal of patient-specific BiovaxID therapy is to prevent lymphoma from returning, after the patient has successfully achieved remission, by harnessing the potency of the immune system to mount a robust and lasting response to specifically target the destruction of lymphoma cells while sparing healthy cells.
BiovaxID holds the potential to become the first cancer vaccine approved for the treatment of non-Hodgkin’s lymphoma.